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A B S T R A C T
Purpose
The beneﬁt of high-dose chemotherapywith autologous stem-cell transplantation (ASCT) as ﬁrst-line
treatment in patients with diffuse large B-cell lymphomas is still a matter of debate. To address this
point, we designed a randomized phase III trial to compare rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP)-14 (eight cycles) with rituximab plus high-dose
sequential chemotherapy (R-HDS) with ASCT.
Patients and Methods
From June 2005 to June 2011, 246 high-risk patients with a high-intermediate (56%) or high (44%)
International Prognostic Index score were randomly assigned to the R-CHOP or R-HDS arm, and 235
were analyzed by intent to treat. The primary efﬁcacy end point of the study was 3-year event-free
survival, and results were analyzed on an intent-to-treat basis.
Results
Clinical response (complete response, 78% v 76%; partial response, 5% v 9%) and failures (no
response, 15% v 11%; and early treatment-related mortality, 2% v 3%) were similar after R-CHOP
versus R-HDS, respectively. After a median follow-up of 5 years, the 3-year event-free survival was
62% versus 65% (P = .83). At 3 years, compared with the R-CHOP arm, the R-HDS arm had better
disease-free survival (79% v 91%, respectively; P = .034), but this subsequently vanished because
of late-occurring treatment-related deaths. No difference was detected in terms of progression-free
survival (65% v 75%, respectively; P = .12), or overall survival (74% v 77%, respectively; P = .64).
Signiﬁcantly higher hematologic toxicity (P , .001) and more infectious complications (P , .001)
were observed in the R-HDS arm.
Conclusion
In this study, front-line intensive R-HDS chemotherapy with ASCT did not improve the outcome of
high-risk patients with diffuse large B-cell lymphomas.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is an
aggressive, but potentially curable, malignancy
accounting for approximately 30% to 35% of all
newly diagnosed B-cell lymphomas.1 The out-
come of the disease is heterogeneous and can be
predicted by validated prognostic scores.2-4 In
young patients with a good prognosis according
to the International Prognostic Index (IPI), the
long-term cure rate after rituximab-containing
conventional chemotherapy programs now ex-
ceeds 80%.5 Long-term results for patients be-
longing to high-risk and high-intermediate–
risk groups have also been improved by similar
chemoimmunotherapy programs, but still remain
unsatisfactory.6,7 In the prerituximab era, high-
dose (HD) chemotherapy programs followed
by autologous stem-cell transplantation (ASCT)
have been proposed as a way to improve the
outcome of high-risk patients with DLBCL8-11;
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however, conﬂicting results have been reported.12-15 Three meta-
analyses have been published, and none found clear evidence for
the use of HD therapy.16-18 The addition of the anti-CD20 antibody
rituximab and HD cytarabine (HD-Ara-C) to the original HD
sequential schedule8 was reported as an innovative program for
patients withmantle cell lymphoma and bonemarrow involvement.19
This rituximab-based HD sequential therapy (R-HDS) was further
developed and proved feasible and active in a multicenter phase II
study in untreated patients with DLBCL with a high age-adjusted
IPI (aaIPI) score.20 Similar results have been obtained in another
phase II study with intensive immunochemotherapeutic protocols
and ASCT.21
The study group Gruppo Italiano Terapie Innovative Linfomi
launched a phase III trial to compare this R-HDS program with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) in adult patients with DLBCLwith high and
high-intermediate risk according to IPI.
PATIENTS AND METHODS
Study Design and Procedures
This open-label, multicenter, randomized phase III trial was spon-
sored by the Ospedale Papa Giovanni XXIII of Bergamo. The study was
conducted in accordance with the International Conference on Harmo-
nization for Good Clinical Practice guidelines and the Declaration of
Helsinki, and was approved by the local ethical committees. Written in-
formed consent was obtained before enrollment. The trial is registered at
www.clinicaltrials.gov as NCT00355199.
Patients
Inclusion criteria were age of 18 to 65 years, biopsy-conﬁrmed CD20-
positive DLBCL according to the 2008 WHO criteria,22 advanced Ann
Arbor stage (stage III to IV or II with bulk deﬁned as $ 10 cm or B
symptoms) without CNS involvement, and no previous treatment. All
patients from 18 to 60 years of age were in an aaIPI high-intermediate or
high-risk group (aaIPI: two and three risk factors, respectively), as were
those 61 to 65 years of age (IPI: 3 and 4 to 5 risk factors, respectively).
Exclusion criteria were concurrent severe heart, kidney, lung, or liver
disease or a positive serology for hepatitis B, hepatitis C, or HIV. Eligible
patients were stratiﬁed by aaIPI or IPI, using the biased coin algorithm to
ensure that the balance of patients’ characteristics were within the ran-
domization strata. Randomization was centralized at Mario Negri Sud
Research Foundation through a Web-based system. A retrospective central
pathology review was performed to determine the cell of origin23-25 by
immunohistochemistry criteria.26
Treatment Plan
Patients enrolled in the control arm received R-CHOP (rituximab
375 mg/m2 intravenously [IV], cyclophosphamide 750 mg/m2 IV, doxo-
rubicin 50mg/m2 IV, vincristine 1.4mg/m2 IV given on day 1 and 100mg/d oral
prednisone given on days 1 to 5), given every 14 days for eight cycles.
The neutropenic phase was supported by granulocyte colony-stimulating
factor (ﬁlgrastrim 5mg/kg subcutaneously given daily or pegﬁlgrastim
subcutaneously given once on day 1 of each cycle). CNS prophylaxis with
intrathecal chemotherapy (methotrexate, Ara-C, corticosteroids) was
given to high-risk patients who, at diagnosis, had inﬁltration of the bone
marrow, testes, Waldeyer ring, cranial air sinuses (including nasal), salivary
glands, and epidural space. In the R-CHOP group, 33 patients (27%)
received intrathecal prophylaxis. The experimental arm (R-HDS)20 was
based on three initial courses of doxorubicin-containing chemotherapy
(ﬁrst doxorubicin administration at 50 mg/m2 IV, then the full dose of
75 mg/m2 IV at 14 and 28 days; vincristine 1.4 mg/m2 IV on days 1, 14,
and 28; oral prednisone 40 mg/m2 on days 1 to 28). Subsequently,
patients received (1) HD cyclophosphamide 7 g/m2 IV (day 1) and
rituximab 375 mg/m2 IV (days 3 and 11), followed by the harvest of
peripheral blood progenitor cells (PBPCs); (2) HD-Ara-C 2 g/m2 IV
(twice a day for 6 days), followed on day 7 by the infusion of 1.5 to 23 106
autologous CD34+ cells/kg and rituximab 375 mg/m2 IV (day 8 and day
16); a second PBPC harvest was scheduled after HD-Ara-C if in-
adequate harvesting was obtained after HD-cyclophosphamide or in
the case of initial bone marrow involvement; (3) HD etoposide 2.4 g/m2
IV (day 1), cisplatin 100 mg/m2 IV (day 2); a small amount of PBPC
(23 106 CD34+ cells/kg) were reinfused following etoposide/cisplatin.
The ﬁnal ASCTwas conditioned with mitoxantrone (60 mg/m2 IV) on
day 25 and melphalan (180 mg/m2 IV) on day 22 or carmustine,
etoposide, cytarabine, and melphalan (carmustine 300 mg/m2 IV on
day 26, etoposide 200 mg/m2 IV on days 25 to 22, Ara-C 200 mg/m2
IVevery 12 h3 eight doses on days25 to22, melphalan 140 mg/m2 IV
on day 21), and supported by PBPC autograft on day 0. The target
harvest for ASCTwas 5 3 106 CD34+ cells/kg. Two additional rituximab
doses were scheduled on days 14 and 24 after ASCT. In both arms,
patients with initial bulky ($ 5 cm) or residual lesions received involved-
ﬁeld radiotherapy within 2 to 3 months after the chemotherapy pro-
gram (Appendix Fig A1, online only). Patients received antiprophylaxis
with sulfamethoxazole/trimethoprim and acyclovir prophylaxis for
Pneumocystis jiroveci and herpes virus.
Evaluation of Response and Toxicity
After four cycles, patients assigned to R-CHOP underwent a ﬁrst
response evaluation (on the basis of a computed tomography scan and
bone marrow biopsy, when indicated). Patients who achieved at least
a partial response (PR) were given four additional courses; patients with
less than a PR or refractory disease were shifted to salvage treatment.
Clinical response was assessed by complete restaging according to Cheson
criteria,27,28 including total-body positron emission tomography (PET).
Residual computed tomography and [18F]ﬂuorodeoxyglucose-PET–
positive masses should be biopsied whenever possible. In the absence of
a conﬁrmed positive biopsy, isolated [18F]ﬂuorodeoxyglucose-PET posi-
tivity was not considered an event. Adverse events were graded according to
the National Cancer Institute Common Terminology Criteria for Adverse
Events (version 3).
Statistical Analysis
The primary end point of the study was event-free survival (EFS),
measured from the time of study entry to any treatment failure, including
death, disease progression, or treatment discontinuation for any reason
(eg, toxicity and patient or medical decision). This composite end point
was chosen for its value in evaluating highly toxic therapies.28 The sample
size of the study protocol was estimated to test a difference of 20% of the
3-year EFS rate between R-CHOP-14 and R-HDS. A sample of 224 patients
randomly assigned to a treatment group (112 for each arm) over a period
of 3 years, with 2 years of additional follow-up, was required for a power of
0.80 with a one-sided a level of .05. We assumed a dropout rate of 10%;
we estimated that 240 patients would be needed to allocate 112 patients
per arm.
According to Cheson guidelines,28 the secondary end points were
response rate, progression-free survival (PFS), disease-free survival (DFS),
overall survival (OS),29 and toxicity. Cox proportional hazards models
were used to estimate the effects of the variables by univariable and
multivariable setting. Proportional hazards assumption was veriﬁed for all
models. Qualitative data were analyzed by the use of the x2 test and, if
appropriate, by Fisher’s exact test. Statistical analyses were performed by R
software (version 3.1.2; R Foundation for Statistical Computing, Vienna,
Austria; https://www.R-project.org/) and SAS (version 9.3; SAS Institute,
Cary, NC) software. All P values are based on two-sided tests and con-
sidered signiﬁcant when , .05.
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RESULTS
Characteristics of Patients and Procedures
From June 2005 to June 2011, 249 patients were assessed
for eligibility (Fig 1). Of the 249 registered patients, three were
excluded because of an unconﬁrmed diagnosis (follicular
lymphoma, n = 1), hepatitis B serology (n = 1), and withdrawn
consent before randomization (n = 1). Of the remaining 246
patients randomly assigned to R-CHOP (n = 126) and R-HDS
(n = 120), the pathology review excluded seven patients who
did not fulﬁl the histology criteria. One patient in the R-CHOP
group (death before starting treatment) and ﬁve in the R-HDS
group (death before starting treatment, n = 1; consent with-
drawal, n = 4) did not receive the allocated treatment. The
characteristics at enrollment of the 235 patients who formed the
intention-to-treat-population are listed in Table 1. The two
arms were well balanced with respect to all presenting features.
Eight patients (3.4%) had a residual low-grade histology. The
median age was 51 years (range, 19 to 66 years), with 26 patients
(11%) . 60 years of age. Adverse clinical features were as
follows: Ann Arbor stage III to IV (92%), elevated lactate
dehydrogenase level (85%), Eastern Cooperative Oncology
Group Performance Status. 1 (62%),$ 2 extranodal sites (44%),
bone marrow inﬁltration (20%), bulky disease (69%), and B
symptoms (59%). Accordingly, the risk score evaluation by IPI was
high-intermediate in 57% of patients and high in 43%. No ran-
domization imbalance was found according to the cell of origin
evaluated retrospectively. The National Comprehensive Cancer
Network–IPI4 was also retrospectively calculated, and 63% of
patients had a risk score . 3.
Clinical Response
A complete response (CR) or unconﬁrmed complete response
(CRu) was observed in 95 of 122 patients treated with R-CHOP
(78%) versus 86 of 113 patients treated with R-HDS (76%; P = .74),
whereas a PRwas documented in six of 122 (5%) and 10 of 113 (9%)
patients, respectively (P = .23). Accordingly, the overall response rate
was 83% versus 85% (P = .65). Progressive disease was observed in
19 of 122 patients (15%) in the R-CHOP arm and 12 of 113 patients
(10%) in the R-HDS arm (P = .36), with only one patient with stable
disease in the R-HDS arm; these were considered primary refractory
patients. One patient in the R-HDS group was not evaluable
(Table 2). In the R-CHOP and R-HDS groups, the treatment was
discontinued in six patients (5%) versus 22 patients (19%), re-
spectively (P , .001), because of infections (one v six), other
toxicities (hematologic, one v six; cardiovascular, one v three; other,
one v two;medical, one v two), or patient decision (one v three). The
ﬁnal autograft was performed in 80 of 113 patients (71%) in the
R-HDS group, with a median of 7.23 106/kg CD34+ cells (range, 3
to 30 3 106/kg). No graft failures were reported. Radiotherapy was
performed in 37 of 122 patients (30%) in the R-CHOP group and
16 of 113 patients (14%) in the R-HDS group (P = .003).
Clinical Outcomes
In the R-CHOP group, 73 of the 95 patients who had achieved
CR/CRu remained alive and in continuous CR (73 of 122 patients;
60%), seven died in CR, and 15 relapsed (12 patients died and three
are alive after achievement of a second CR). In the R-HDS group, of
the 86 patients who had achieved CR/CRu, 74 remained alive in
continuous CR (74 of 113; 65%), six died in CR, and six expe-
rienced relapse (four later died, two are still alive). Of the six
Patients randomly assigned (n = 246)
Intent-to-treat population (n = 235)
Assigned to R-CHOP (n = 126) Assigned to R-HDS (n = 120)
Unconfirmed diagnosis (n = 4)
Analyzed (n = 122)
Died before treatment (n = 1) Died before treatment (n = 1)
Analyzed (n = 113)
Follicular NHL     (n = 1)
Hepatitis B           (n = 1)
Patient's refusal  (n = 1)
Excluded
Unconfirmed diagnosis (n = 3)
Consent withdrawn (n = 4)
Patients assessed for eligibility for the study protocol (N = 249)
Fig 1. CONSORT diagram of the study.
NHL, non-Hodgkin lymphoma; R-CHOP, rit-
uximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone; R-HDS, rituximab
plus high-dose sequential chemotherapy.
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patients who achieved a partial remission after R-CHOP, three
remained alive, two experienced disease progression (one died and
one is alive in second CR), and one was lost to follow-up. Of the 10
patients treated with R-HDS who were judged as partial remitters,
three are alive without additional treatment, ﬁve experienced
disease progression (three died and two are in CR following ad-
ditional treatment), one died of a secondary cancer, and one died of
treatment-related toxicity. A CNS progression/relapse occurred in
seven of 122 patients (5.7%) in the R-CHOP arm and ﬁve of 113
(4.4%) in the R-HDS arm (P = .65). Of the 19 patients who had
progressive disease after R-CHOP, 13 died and six are alive. All 12
patients with progressive disease after receiving R-HDS died. The
patient with stable disease was lost to follow-up.
After a median follow-up of 5 years (range, 0.05 to 9.49), by an
intent-to-treat analysis, the 3-year EFS was 62% (95% CI, 54% to
71%) for patients treated with R-CHOP versus 65% (95% CI, 56%
to 74%) for patients treated with R-HDS (P = .83; hazard ratio,
0.99; 95% CI, 0.66 to 1.48; Fig 2A). The same lack of difference was
observed when data were analyzed within the IPI subgroups (Figs
2B and 2C). Similarly, treatments did not signiﬁcantly affect the
3-year PFS, which was 65% in the R-CHOP arm (95% CI, 57% to
74%) versus 75% (95% CI, 67% to 83%; P = .119) after R-HDS in
the whole population (Fig 2D), as well as within IPI subgroups
(Figs 2E and 2F). Interestingly, the 3-year DFS was better in the
experimental arm, at 79% (95%CI, 71% to 87%) versus 91% (95%
CI, 85% to 97%) in the R-CHOP and R-HDS arms, respectively
(P = .033), even though this difference was lost after a longer
follow-up (Fig 3A). No difference was found in terms of OS, at 74%
(95% CI, 67% to 82%) in the R-CHOP arm versus 77% (95% CI,
70% to 86%) in the R-HDS arm (P = .64), no matter what the IPI
risk subgroup was (Figs 3D, 3E, and 3F). Interestingly, the sub-
group analysis describing the outcome of patients who did not
discontinue the allocated treatment because of medical or patient
decision or toxicity showed a signiﬁcant beneﬁt of the R-HDS
program in terms of PFS and DFS, but not OS (Appendix Fig A2).
By univariable analysis, factors affecting age, performance
status, and IPI subgroups showed a signiﬁcant impact on EFS, PFS,
and OS. Bulky disease was also signiﬁcant on EFS (Appendix Table
A1, online only). No evidence of differential beneﬁt according to
the cell of origin emerged from treatment intensiﬁcation. By
multivariable analysis, IPI remained the only factor signiﬁcantly
affecting the same outcomes (Appendix Table A2, online only).
Table 2. Response to Treatment and Causes of Death
Response to Treatment
R-CHOP,
No. (%)
(n = 122)
R-HDS, No. (%)
(n = 113)
Complete/unconﬁrmed complete response 95 (78) 86 (76)
Partial response 6 (5) 10 (9)
Progressive/stable disease 19 (15) 13 (11)
Lost to follow-up — 1 (0.8)
Overall response rate 101 (83) 96 (85)
Causes of death
Total No. of deaths 35 (29) 30 (26)
Early death* 2 (1.6) 3 (2.6)
Disease related
After progression 14 (11) 15 (13)
After relapse 12 (10) 4 (3.5)
Treatment related†
Infections 2 (1.6) 1 (0.9)
Heart failure 1 (0.8) 2 (1.8)
Secondary malignancy 2 (1.6) 3 (2.7)
Other 2 (1.6) 2 (1.8)
Abbreviations: R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vin-
cristine, and prednisone; R-HDS, rituximab plus high-dose sequential
chemotherapy.
*Within 100 days from randomization.
†Death in remission (two patients in partial remission, 13 in complete
remission).
Table 1. Demographic Characteristics by Study Arm
Characteristic
All Patients,
No. (%)
(N = 235)
R-CHOP,
No. (%)
(n = 122)
R-HDS,
No. (%)
(n = 113) P
Age, years
Median (range) 51 (19-66) 49 (19-66) 53 (19-65) .44
# 60 209 (89) 108 (89) 101 (89) .83
. 60 26 (11) 14 (11) 12 (11)
Sex
Male 136 (58) 71 (58) 65 (58) .92
Female 99 (42) 51 (42) 48 (42)
ECOG performance status
0 37 (16) 21 (17) 16 (14) .36
1 53 (23) 25 (20) 28 (25)
2 117 (50) 65 (53) 52 (46)
3 28 (12) 11 (9) 17 (15)
Ann Arbor clinical stage
II 19 (8) 9 (7) 10 (9) .91
III 54 (23) 28 (23) 26 (23)
IV 162 (69) 85 (70) 77 (68)
Bulky disease*
No 72 (31) 37 (30) 35 (31) .88
Yes 162 (69) 85 (70) 77 (68)
B symptoms*
No 93 (40) 51 (42) 42 (37) .54
Yes 138 (59) 70 (57) 68 (60)
Bone marrow inﬁltration*
No 177 (75) 93 (76) 84 (74) .86
Yes 47 (20) 24 (20) 23 (20)
No. of extranodal sites
0-1 132 (56) 70 (57) 62 (55) .70
$ 2 103 (44) 52 (43) 51 (45)
Elevated LDH (ratio to ULN)
# 1 34 (14) 17 (14) 17 (15) .93
. 1-# 3 165 (70) 87 (71) 78 (69)
. 3 36 (15) 18 (15) 18 (16)
IPI†
High-intermediate risk 133 (57) 67 (55) 66 (58) .59
High risk 102 (43) 55 (45) 47 (42)
NCCN IPI
# 3 87 (37) 45 (37) 42 (37) .96
. 3 148 (63) 77 (63) 71 (63)
Cell of origin
Non-GCB 112 (48) 54 (44) 58 (51) .68
GCB 64 (27) 35 (29) 29 (26)
PML 27 (11) 14 (11) 13 (12)
NE 32 (14) 19 (16) 13 (12)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; GCB, germinal
center B-cell–like; IPI, International Prognostic Index; LDH, lactate de-
hydrogenase; NCCN, National Comprehensive Cancer Network; NE, not
evaluable for lack of material; PML, primary mediastinal lymphoma; R-CHOP,
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone;
R-HDS, rituximab plus high-dose sequential chemotherapy; UNL, upper limit
of normal range.
*Onemissing datum in the R-HDS arm for bulky disease; three missing data for
B symptoms in the R-HDS arm and one in the R-CHOP arm; six and ﬁve missing
data for bone marrow in the R-HDS arm and in the R-CHOP arm, respectively.
†High-intermediate: age-adjusted IPI = 2, IPI = 3; high risk: age-adjusted IPI = 3,
IPI = 4-5.
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Toxicity
A lower rate of grade 3 to 4 hematologic toxicity was
recorded in the R-CHOP arm compared with the R-HDS arm,
with at least one episode of neutropenia in 34% versus 84%
of patients (P , .001), anemia in 15% versus 71% of patients
(P , .001), and thrombocytopenia in 5% versus 86% of pa-
tients (P , .001; Table 3). Patients receiving R-CHOP had
fewer episodes of mucositis, diarrhea, nausea, and vomiting
(11% v 29%; P , .001). A deeper neutropenia contributed
to a higher frequency of severe infections in R-HDS pa-
tients (54% v 8%; P, .001). Sensory neurologic adverse effects
were more frequent after R-CHOP (7% v 0%), possibly as
a consequence of the higher cumulative dose of vincristine
received during treatment. A lower number of adverse events
occurred in the R-CHOP arm versus the R-HDS arm (14 v
45; P , .001), including those classiﬁed as serious (ﬁve v 24;
P , .001).
Cause of Death
Thirty-ﬁve patients (29%) in the R-CHOP group and 30
(26%) in the R-HDS group died. Two patients in the R-CHOP
group and three in R-HDS group died within 100 days of diagnosis
(early death). In the R-CHOP and R-HDS groups, 26 and 19
patients died as a result of disease, whereas seven and eight
responding patients , respectively, died as a result of treatment-
related toxicities (Table 2).
DISCUSSION
This randomized phase III trial demonstrates that the clinical
outcome of patients with high-risk DLBCL treated with R-CHOP
or an intensive R-HDS program is comparable. Both treatments
provided similar results in terms of overall response rate and long-
term outcomes. Therefore, the primary objective of this study to
20
40
60
80
100
Time (years)
Ev
en
t-F
re
e 
Su
rv
iv
al
 (%
)
R−CHOP
R−HDS
No. at risk
P = .9542
At 3 years: P = .8282
62%
65%
R−CHOP
R−HDS
A
20
40
60
80
100
Time (years)
Pr
og
re
ss
io
n-
Fr
ee
 S
ur
vi
va
l (
%
)
R−CHOP
R−HDS
No. at risk
P = .2694
At 3 years: P = .1195
65%
75%
R−CHOP
R−HDS
D
0 2 4 6 8
122 76 67 42 12
113 72 61 35 10
0 2 4 6 8
122 79 70 45 12
113 82 70 40 11
20
40
60
80
100
Time (years)
Ev
en
t-F
re
e 
Su
rv
iv
al
 (%
)
R−CHOP
R−HDS
No. at risk
P = .8608
At 3 years: P = .7326
68%
71%
R−CHOP
R−HDS
B
20
40
60
80
100
Time (years)
Pr
og
re
ss
io
n-
Fr
ee
 S
ur
vi
va
l (
%
)
R−CHOP
R−HDS
No. at risk
P = .6622
At 3 years: P = .3962
74%
80%
R−CHOP
R−HDS
E
4 6 8
67 46 40 27 9
66 47 41 22 7
0 2
0 2 4 6 8
67 49 43 30 9
66 52 46 24 7
20
40
60
80
100
Time (years)
Ev
en
t-F
re
e 
Su
rv
iv
al
 (%
)
R−CHOP
R−HDS
No. at risk
P = .7982
At 3 years: P = .8834
55%
55%
R−CHOP
R−HDS
C
20
40
60
80
100
Time (years)
Pr
og
re
ss
io
n-
Fr
ee
 S
ur
vi
va
l (
%
)
R−CHOP
R−HDS
0 2 4 6 8
55 30 27 15 3
47 25 20 13 3
0 2 4 6 8
55 30 27 15 3
47 30 24 16 4
No. at risk
P = .3425
At 3 years: P = .2299
55%
67%
R−CHOP
R−HDS
F
Fig 2. Event-free survival (EFS) and progression-free survival (PFS) curves according to treatment randomization. (A) EFS in all patients; (B) EFS in high-intermediate–risk
patients; (C) EFS in high-risk patients; (D) PFS in all patients; (E) PFS in high-intermediate–risk patients; and (F) PFS in high-risk patients. EFSwasmeasured from the time of
study entry to any treatment failure, including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference,
initiation of new antilymphoma treatment, or death) or date of the last follow-up visit. PFS was deﬁned as the time from study entry to disease progression or death as
a result of any cause or date of the last follow-up visit. R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-HDS, rituximab plus high-
dose sequential chemotherapy.
www.jco.org © 2016 by American Society of Clinical Oncology 5
Randomized Trial of R-CHOP Versus R-HDS in High-Risk DLBCL
MILANO on October 10, 2016 from 89.96.77.212
Information downloaded from jco.ascopubs.org and provided by at FONDAZIONE ISTITUTO NAZIONALE TUMORI
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
improve the EFS by the use of HD chemotherapy and ASCT was
not achieved. Our study was conducted entirely in the rituximab
era and was offered only to a homogeneous group of patients with
DLBCL with unfavorable risk factors at diagnosis. Our results
indicate that CHOP chemotherapy, optimally supplemented by
eight doses of rituximab,30 remains the standard of care also for
this group of patients at higher risk for disease resistance or re-
currence. In a multicenter setting, R-HDS therapy had a higher rate
of acute hematologic and infectious toxicities and was more dif-
ﬁcult to complete when considering the higher rate of treatment
discontinuation. The appropriate long-term follow-up allowed
observation of better DFS at 3 years after R-HDS, although the
robustness of the remission achieved after this intensive treatment
vanished subsequently with the occurrence of late events.
When this study was designed, R-CHOP-14 treatment for eight
cycles was selected as the control arm on the basis of the prelim-
inary data of the German study group, which suggested an advantage
of the dose-dense rituximab-based chemoimmunotherapy in elderly
patients with DLBCL,31 and to avoid the possibility that a potential
superior result of the intensive experimental arm could be attrib-
utable to a weaker conventional therapy. Nonetheless, the results of
our study, which enrolled only high-risk (IPI 2 to 3) patients, are
similar to those reported by using R-CHOP (3 six cycles every
14 days plus two cycles of rituximab or3 eight cycles every 21 days)32
and comparable to those achieved when adopting an induction
therapy also including etoposide.33
On the contrary, compared with standard R-CHOP, in-
tensiﬁed immunochemotherapy with rituximab, doxorubicin,
cyclophosphamide, vindesine, bleomycin, and prednisone signif-
icantly improved survival of low-risk patients,34 and this beneﬁt
was mostly observed in patients with non–germinal center B-cell
(GCB) DLBCL.35 In our study, similar to the report on the phase II
trial we previously published,20 the GCB versus non-GCB cell of
origin did not predict a different outcome and was at variance with
what was reported by the LNH03-2B study; we did not observe
a better outcome among GCB patients treated with high-dose
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Fig 3. Disease-free survival (DFS) and overall survival (OS) curves according to treatment randomization. (A) DFS in all patients; (B) DFS in high-intermediate–risk patients;
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prednisone; R-HDS, rituximab plus high-dose sequential chemotherapy.
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chemotherapy. However, in the French study,34 patients with only
one aaIPI adverse factor were enrolled, which could explain better
tolerance and results from the experimental treatment. Overall, the
clinical value of a stratiﬁcation on the basis of an immunostaining
algorithm remains controversial with conﬂicting results.36,37 The
lack of information about double- or triple-hit lymphomas
remains a potential limitation of our study.38,39 The SWOG
(Southwest Oncology Group)-9704 trial, which included different
subtypes of B-cell and T-cell lymphomas, found that early con-
solidation with ASCT improved the PFS of patients with high-
intermediate risk or high risk who had a response to induction
chemotherapy (2-year PFS, 69% v 55%) without any difference in
OS between the two treatment arms.40 It is worth noting that the
superiority of ASCTwas limited to 35% of patients with high-risk
IPI in whom either the PFS or OS was better than that of patients
who received conventional chemotherapy, whereas in the pre-
vailing group of patients with high-intermediate risk, there was no
difference in terms of PFS and OS between the two treatment arms.
Preliminary results from another Italian study reported an ad-
vantage in terms of PFS but not OS in chemosensitive patients who
proceeded to ASCT.41
In conclusion, this randomized trial indicates that both dose-
dense R-CHOP for eight cycles and R-HDS followed by autograft
are equally effective in high-risk patients with DLBCL.Whether the
addition of new drugs, such as lenalidomide42 and ibrutinib43 or
monoclonal antibodies such as obinotuzumab,44 to R-CHOP
therapy will be able to improve the outcome of high-risk patients
with DLBCL is still under investigation.
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Appendix
Table A1. Univariable Analysis
Characteristic
EFS
(n = 235; events = 93)
PFS
(n = 235; events = 79)
DFS
(n = 181; events = 34)
OS
(n = 235; events = 65)
HR (95% CI) P* HR (95% CI) P* HR (95% CI) P* HR (95% CI) P*
Treatment arm
R-CHOP 1.00 1.00 1.00 1.00
R-HDS 0.99 (0.66 to 1.48) .9536 0.78 (0.50 to 1.22) .2702 0.6 (0.29 to 1.21) .1501 0.93 (0.57 to 1.52) .7796
Age, years
# 60 1.00 1.00 1.00 1.00
. 60 1.86 (1.07 to 3.23) .0284 1.93 (1.06 to 3.5) .0306 2.39 (0.99 to 5.77) .0535 1.95 (1.02 to 3.73) .0437
Sex
F 1.00 1.00 1.00 1.00
M 1.15 (0.76 to 1.74) .5123 1.02 (0.65 to 1.6) .9198 0.8 (0.41 to 1.58) .5232 0.88 (0.54 to 1.44) .621
ECOG performance status
0 1.00 1.00 1.00 1.00
1 1.24 (0.55 to 2.80) .6077 1.70 (0.65 to 4.44) .2745 1.46 (0.37 to 5.86) .59 2.28 (0.74 to 7.01) .1485
2 2.41 (1.19 to 4.86) .0143 3.28 (1.41 to 7.65) .0059 3.1 (0.93 to 10.35) .0662 3.61 (1.29 to 10.1) .0143
3 1.6 (0.65 to 3.94) .3059 1.93 (0.67 to 5.58) .2222 1.46 (0.29 to 7.23) .6442 2.76 (0.83 to 9.16) .0978
Ann Arbor clinical stage
II 1.00 1.00 1.00 1.00
III 1.26 (0.51 to 3.15) .6144 1.06 (0.38 to 2.91) .9147 0.44 (0.1 to 1.97) .2829 1.03 (0.33 to 3.18) .9634
IV 1.42 (0.61 to 3.26) .4146 1.46 (0.59 to 3.64) .4149 1.16 (0.35 to 3.82) .8084 1.53 (0.55 to 4.24) .4142
Bulky disease
No 1.00 1.00 1.00 1.00
Yes 0.55 (0.36 to 0.83) .0043 0.79 (0.5 to 1.26) .3216 0.52 (0.27 to 1.03) .0599 0.8 (0.48 to 1.35) .4043
B symptoms*
No 1.00 1.00 1.00 1.00
Yes 1.15 (0.75 to 1.76) .5142 1.17 (0.74 to 1.85) .5129 1.31 (0.65 to 2.64) .4546 1.25 (0.75 to 2.08) .3953
BM inﬁltration
No 1.00 1.00 1.00 1.00
Yes 0.94 (0.56 to 1.58) .8134 0.89 (0.51 to 1.57) .6937 1.61 (0.79 to 3.31) .1935 0.97 (0.53 to 1.79) .9253
No. of extranodal sites
0-1 1.00 1.00 1.00 1.00
$ 2 1.34 (0.89 to 2.02) .1571 1.27 (0.82 to 1.98) .2881 1.25 (0.64 to 2.45) .516 1.35 (0.83 to 2.2) .2239
Elevated LDH (ratio to ULN)
# 1 1.00 1.00 1.00 1.00
. 1 # 3 0.83 (0.47 to 1.46) .5217 0.88 (0.47 to 1.66) .6897 0.61 (0.25 to 1.45) .2616 0.95 (0.46 to 1.97) .8910
. 3 1.24 (0.63 to 2.44) .5318 1.69 (0.82 to 3.49) .1528 1.57 (0.58 to 4.21) .3736 2.17 (0.97 to 4.83) .0584
IPI
Intermediate-high 1.00 1.00 1.00 1.00
High 1.78 (1.18 to 2.67) .0058 2.08 (1.33 to 3.25) .0013 1.63 (0.83 to 3.21) .1536 2.17 (1.32 to 3.55) .0022
NCCN IPI
# 3 1.00 1.00 1.00 1.00
. 3 1.81 (1.14 to 2.87) .0112 1.82 (1.1 to 3.00) .0190 1.67 (0.80 to 3.50) .1712 1.58 (0.92 to 2.69) .0960
Cell of origin
GCB 1.00 1.00 1.00 1.00
Non-GCB 0.90 (0.56 to 1.45) .6638 0.75 (0.45 to 1.26) .2848 0.72 (0.33 to 1.58) .4100 0.77 (0.43 to 1.36) .3692
PML 0.54 (0.24 to 1.24) .1458 0.62 (0.27 to 1.43) .2629 0.41 (0.09 to 1.86) .2485 0.76 (0.32 to 1.80) .5304
NE 1.01 (0.53 to 1.92) .9715 1.02 (0.52 to 1.99) .9621 1.13 (0.44 to 2.92) .7996 0.94 (0.44 to 2.01) .8699
Abbreviations: BM, bone marrow; DFS, disease-free survival; EFS, event-free survival; GCB, germinal center B-cell–like; HR, hazard ratio; IPI, International Prognostic
Index; LDH, lactate dehydrogenase; NCCN, National Comprehensive Cancer Network; NE, not evaluable for lack of material; OS, overall survival; PFS, progression-free
survival; PML, primary mediastinal lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-HDS, rituximab plus high-dose
sequential chemotherapy; ULN, upper limit of normal.
*Result of Wald test in a univariate Cox model.
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Table A2. Multivariable Analysis
Characteristic
EFS
(n = 235; events = 93)
PFS
(n = 235; events = 79)
DFS
(n = 181; events = 34)
OS
(n = 235; events = 65)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Treatment arm
R-CHOP 1.00 1.00 1.00 1.00
R-HDS 1.05 (0.7 to 1.6) .8011 0.84 (0.53 to 1.32) .4464 0.58 (0.29 to 1.2) .142 1 (0.61 to 1.64) .9946
Sex
F 1.00 1.00 1.00 1.00
M 1.16 (0.76 to 1.76) .4965 1.01 (0.64 to 1.59) .974 0.84 (0.42 to 1.68) .6153 0.9 (0.55 to 1.48) .6785
Age
# 60 1.00 1.00 1.00 1.00
. 60 1.66 (0.92 to 2.98) .0905 1.7 (0.91 to 3.18) .0973 2.01 (0.8 to 5.05) .1371 1.74 (0.88 to 3.43) .1097
BM inﬁltration
No 1.00 1.00 1.00 1.00
Yes 0.84 (0.5 to 1.43) .5232 0.81 (0.45 to 1.43) .4599 1.47 (0.7 to 3.08) .3037 0.87 (0.47 to 1.62) .6646
B symptoms
No 1.00 1.00 1.00 1.00
Yes 1.09 (0.7 to 1.69) .7004 1.09 (0.68 to 1.76) .7093 1.3 (0.63 to 2.68) .4824 1.2 (0.71 to 2.03) .4899
IPI
Intermediate-high 1.00 1.00 1.00 1.00
High 1.7 (1.11 to 2.62) .0149 1.95 (1.23 to 3.11) .0049 1.48 (0.73 to 3) .2818 1.99 (1.19 to 3.33) .0084
Cell of origin
GCB 1.00 1.00 1.00 1.00
Non-GCB 0.82 (0.5 to 1.33) .4175 0.7 (0.41 to 1.18) .1839 0.71 (0.32 to 1.58) .4029 0.7 (0.39 to 1.25) .2304
PML 0.53 (0.23 to 1.22) .1365 0.6 (0.26 to 1.39) .2326 0.39 (0.09 to 1.8) .2304 0.74 (0.31 to 1.76) .4898
NE 0.97 (0.5 to 1.89) .9327 0.99 (0.5 to 1.98) .9809 1.03 (0.38 to 2.76) .953 0.88 (0.41 to 1.92) .7563
Abbreviations: BM, bone marrow; DFS, disease-free survival; EFS, event-free survival; GCB, germinal center B-cell–like; HR, hazard ratio; IPI, International Prognostic
Index; NE, not evaluable for lack of material; OS, overall survival; PFS, progression-free survival; PML, primary mediastinal lymphoma; R-CHOP, rituximab plus cy-
clophosphamide, doxorubicin, vincristine, and prednisone; R-HDS, rituximab plus high-dose sequential chemotherapy.
www.jco.org © 2016 by American Society of Clinical Oncology
Randomized Trial of R-CHOP Versus R-HDS in High-Risk DLBCL
MILANO on October 10, 2016 from 89.96.77.212
Information downloaded from jco.ascopubs.org and provided by at FONDAZIONE ISTITUTO NAZIONALE TUMORI
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
R
an
d
o
m
iz
at
io
n
VP16
CDDP
Mitox +
L-PAM/
BEAM
D
ia
g
n
o
si
s
R-CHOP
Day 1 Day 15 Day 29 Day 43
APO APO APO HD-CTX HD-Ara-C
Day 1 Day 15 Day 29 Day 50 Day 71
D
ay 60
D
ay 90
CR or PR
PD or SD
CR or CRu
< CR
Day 112 Day 133
Salvage
therapy
Fi
n
al
ev
al
u
at
io
n
Fi
n
al
ev
al
u
at
io
n
< CR
PBPC harvest
PBPC reinfusion (1.5 2 x 106/kg, day 7)
Additional PBPC harvest
PBPC reinfusion
(≥ 5 x 106/kg)
PBPC reinfusion (2 x 106/kg, day 1)
R-CHOP
Day 61
R-CHOP
Day 75
R-CHOP
Day 89
R-CHOP
Day 103
< CR
In
te
rm
ed
ia
te
ev
al
u
at
io
n
In
te
rm
ed
ia
te
ev
al
u
at
io
n
R-CHOP R-CHOP R-CHOP
APO: Doxorubicin (50 mg/m2 IV on day 1 for cycle 1)
and 75 mg/m2 IV on day 1 for cycle 2-3)
Vincristine (1.4 mg/m2 IV on day 1)
Prednisone (40 mg/m2 on days 1-28)
HDCTX: Cyclophosphamide (7 g/m2on day 1)
Rituximab (on days 3 and 11)
Filgrastim (5 µg/kg on days 2-10 and 10 µg/kg on day 11 to PBPC harvest)
HD-Ara-C: Cytarabine (2 g/m2on days 1-6)
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Prednisone (100 mg/m2 on days 1-5)
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Fig A1. Study design. APO, doxorubicin 50 mg/m2 IV followed by the full dose of 75 mg/m2 IV at 14 and 28 days, vincristine 1.4 mg/m2 IV on days 1, 14, and 28, and oral
prednisone 40 mg/m2 on days 1 to 28; BEAM, carmustine, etoposide, cytarabine, melphalan; CDDP, cisplatin; CR, complete response; CRu, complete response un-
conﬁrmed; HD-Ara-C, high-dose cytarabine; HD-CTX, high-dose cyclophosphamide; IV, intravenously; L-PAM, melphalan; mitox, mitoxantrone; PBPC, peripheral blood
progenitor cells; PD, progressive disease; PR, partial response; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SD, stable disease;
VP16, etoposide.
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Fig A2. (A) Progression-free survival, (B) disease-free survival, and (C) overall survival of patients not discontinuing the allocated treatment because of toxicities (medical
or patient’s decision). R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-HDS, rituximab plus high-dose sequential chemotherapy.
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